A bifunctional peptide–selenium nanocomposite for lysosomal degradation of PD-L1 and enhanced cancer immunotherapy
BackgroundImmune checkpoint blockade (ICB) therapies that inhibit PD-1/PD-L1 signaling have revolutionized oncology, yet their benefits are constrained by limited penetration into tumor tissues, inability to eliminate intracellular PD-L1, and the emerg…